| INTRODUCTION
Microphthalmia-associated transcription factor (MITF) was first identified as the gene mutated in a strain of transgenic mice displaying a phenotype of white coat, microphthalmia, and deafness (Hodgkinson et al., 1993) . Further analysis of Mitf in mice (Opdecamp et al., 1997) and its ortholog mitfa in zebrafish (Lister, Robertson, Lepage, Johnson, & Raible, 1999) showed that MITF is required for development of the melanocyte lineage from the neural crest (NC). Forced expression of MITF was sufficient to induce ectopic melanocytes in zebrafish (Lister et al., 1999 ) and the expression of at least some melanocyte differentiation genes in cultured mouse cells (Hou, Arnheiter, & Pavan, 2006; Tachibana et al., 1996) . This prominent role in melanocyte development has led MITF to be labeled the "master regulator" of melanocytes.
All nine described isoforms of MITF share a basic helix-loop-helix leucine zipper (bHLH-Zip) DNA-binding/dimerization domain and two transactivation domains (Hartman & Czyz, 2015; Levy, Khaled, & Fisher, 2006) . The shortest isoform, MITF-M, is specifically expressed in melanocytes and binds an extended canonical E-box motif known as the M-Box, 5′-TCATGTGCT-3′ (Figure 1a ; Hartman & Czyz, 2015) .
Initial in vitro studies on specific genes, using electromobility shift assays (EMSA), chromatin immunoprecipitation (ChIP), and reporter assays, showed that MITF directly regulates the expression of genes that encode melanin synthesis enzymes (e.g., TYR, TYRP1, DCT) and melanosome proteins (e.g., PMEL, MLANA, RAB27A), as well as proteins involved in the cell cycle (e.g., CDKN1A, CDKN2A, TBX2, CDK2) and cell survival (e.g., BCL2, BIRC7, HIF1A, MET) (reviewed in Levy et al., 2006; Cheli, Ohanna, Ballotti, & Bertolotto, 2010; Vachtenheim & Borovansky, 2010) . More recently, ChIP-seq profiles have identified many additional candidate MITF targets within these and other | 455 SEBERG Et al. categories, including DNA replication and repair, cell proliferation, and mitosis Webster et al., 2014) . The broad range of function among MITF-target genes confirmed the importance of this transcription factor in melanocyte development and suggested that it plays a complex role in melanoma tumorigenesis.
To explain the paradoxical observation that MITF could both promote and inhibit proliferation of melanoma cells, Colin Goding et al. proposed that the level of MITF activity is a determinant of phenotype switching in melanoma tumor cells. According to this "MITF rheostat" model, a high level of MITF activity promotes differentiation, mid-level activity promotes proliferation, low-level activity promotes an invasive, stem cell-like phenotype, and the absence of MITF activity causes senescence or cell death (Figure 2 ; Carreira et al., 2006; Goding, 2011; Hoek & Goding, 2010) . Resistance to BRAF inhibitors in melanoma also appears to be affected by MITF levels (Muller et al., 2014) . How is the level of the MITF rheostat set? First, the measure of MITF activity depends upon the level of MITF expression. Multiple transcription factors positively regulate MITF expression in melanocytes, including PAX3, SOX10, CREB, and LEF1 (reviewed in Goding, 2000; Steingrimsson, Copeland, & Jenkins, 2004; Wan, Hu, & He, 2011; Wellbrock & Arozarena, 2015) , while BHLHE40, ATF4, BRN2/POU3F2, and GLI2 repress it (Cheli et al., 2012; Falletta et al., 2017; Goodall et al., 2008; Pierrat, Marsaud, Mauviel, & Javelaud, 2012) . Second, MITF activity is affected by post-translational modifications of MITF, such as phosphorylation (Hemesath, Price, Takemoto, Badalian, & Fisher, 1998; Takeda et al., 2000; Wu et al., 2000) and sumoylation (Bertolotto et al., 2011; Miller, Levy, Davis, Razin, & Fisher, 2005; Murakami & Arnheiter, 2005 ; reviewed in Goding, 2000; Steingrimsson et al., 2004; Wellbrock & Arozarena, 2015) . Finally, the presence of other transcription factors that bind the same regulatory elements as MITF, or to separate elements associated with the same gene, will determine which MITFtarget genes are expressed and at what levels. Evidence for the role of such factors includes the observation that forced ectopic expression of MITF in non-melanocyte cell types is insufficient to induce a full melanocyte differentiation program (Gaggioli, Busca, Abbe, Ortonne, & Ballotti, 2003; Hou et al., 2006; de la Serna et al., 2006; Vachtenheim, Novotna, & Ghanem, 2001; Yang et al., 2014) . In addition, a combination of genetic studies and mathematical modeling of the melanocyte gene regulatory network (GRN) implied the existence of transcriptional regulators other than MITF in melanocyte differentiation (Greenhill, Rocco, Vibert, Nikaido, & Kelsh, 2011) . Subsequently, MITF was shown to interact with chromatin modifiers CBP/p300 Sato et al., 1997) and SWI/SNF complexes containing BRM or BRG1 (Keenen, Qi, Saladi, Yeung, & de la Serna, 2010; Laurette et al., 2015; de la Serna et al., 2006) , as well as with various transcription factors, which are the subject of this review. We focus on SOX10, YY1, and TFAP2A, three transcription factors for which ChIP-seq studies have shown frequent co-occupancy with MITF in melanocytes, placing particular emphasis on TFAP2A as it has not previously been discussed in other reviews of transcriptional regulation in melanocytes. We then briefly summarize evidence that several other transcription factors act together with MITF at specific regulatory elements. Throughout this review, we use the term "MITF collaborators" to describe transcription factors that bind one or more of the same regulatory elements as F I G U R E 1 Protein domains of MITF, SOX10, YY1, and TFAP2A. (a-d) Protein domains and consensus binding motifs for human (a) MITF-M, (b) SOX10, (c) YY1, and (d) TFAP2A. Highlighted domains include those involved in transcriptional activation (red), DNA-binding (blue), dimerization (green), and repression (yellow). A red bar denotes the conserved PY motif in TFAP2A. Domain information is modified from MITF-M (Goding, 2000; Hartman & Czyz, 2015) , SOX10 (Mollaaghababa & Pavan, 2003) , YY1 (Atchison, 2014; Thomas & Seto, 1999) , and TFAP2A (Eckert et al., 2005; Williams & Tjian, 1991) . Consensus binding motif for MITF-M is modified from (Cheli et al., 2010) , and all other motifs are modified from JASPAR (Sandelin, Alkema, Engstrom, Wasserman, & Lenhard, 2004) MITF. In most cases, it remains to be determined whether they are also "MITF cofactors," defined as proteins that physically interact with MITF to increase its activity.
The studies reviewed here span several model systems, including zebrafish, mouse, and human. Genetic studies suggest that the GRNs governing melanocyte development are largely conserved among vertebrates. By contrast, the concordance between individual binding loci in human and mouse is low (Cheng et al., 2014; Odom et al., 2007; Schmidt et al., 2010; Seberg et al., 2017) . Even among closely related Drosophila species, mRNA expression levels were found to be much more conserved than the transcription factor binding sites that regulate them (Paris et al., 2013) . This reflects the rapid rate at which transcription factor binding sites are gained and lost, and results in distinct binding sites in different model organisms, while the association between particular transcription factors and genes is largely conserved among them.
| SOX10
SOX10 is one of over 30 SRY-box transcription factors, which are characterized by a conserved high-mobility group (HMG) DNAbinding domain recognizing the sequence motif 5′-T/AT/ACAAAG-3′
( Figure 1b ; Bowles, Schepers, & Koopman, 2000) . In particular, members of the SOXE group (SOX8, SOX9, and SOX10) are early markers of specified NC and later function in the differentiation of various NC derivatives (Haldin & LaBonne, 2010) . Consistent with a prominent role for SOX10 in NC, zebrafish sox10 (colourless, cls) mutants display a severe reduction of melanoblasts, apparently due to failed specification, impaired migration, and eventual apoptosis of the nonectomesenchymal NC cell population from which they arise (Dutton et al., 2001; Kelsh & Eisen, 2000) . Mice homozygous for the Dominant megacolon (Dom) mutation in Sox10 are embryonic lethal, while heterozygotes have a white belly spot pigmentation phenotype, as well as loss of enteric ganglia and neurons derived from the cranial NC (Herbarth et al., 1998; Hou et al., 2006) . SOX10 mutations in humans have been associated with Waardenburg syndrome type II and type IV (Waardenburg-Shah), which commonly feature hypopigmentation of the skin, hair, and eyes (Bondurand et al., 2007; Pingault et al., 1998) .
In addition to functioning in the maintenance and proliferation of NC, SOX10 acts in NC cells to specify the melanocyte lineage by directly activating expression of MITF (Bondurand et al., 2000; Lee, Goodall, Verastegui, Ballotti, & Goding, 2000; Potterf, Furumura, Dunn, Arnheiter, & Pavan, 2000; Verastegui, Bille, Ortonne, & Ballotti, 2000) . In zebrafish sox10 (cls) mutants, restoration of mitfa expression under the sox10 promoter appears to fully rescue melanocyte development, suggesting that Sox10 is required to induce the melanocyte lineage through Mitfa but is not otherwise necessary for the terminal differentiation of melanocytes (Elworthy, Lister, Carney, Raible, & Kelsh, 2003 (Jiao et al., 2004; Murisier, Guichard, & Beermann, 2006 Potterf et al., 2001) . The ability of SOX10 to directly activate pigmentation genes in addition to regulating their expression through MITF revealed the need for a more comprehensive profile of SOX10 transcriptional targets in melanocytes.
To assess the direct targets of SOX10 in melanocytes, Fufa et al. The SOX10-occupied regulatory elements that are associated with genes activated by SOX10 were enriched for MITF binding motifs, whereas those near genes that are repressed by SOX10 were not (Fufa et al., 2015) , indicating that interactions with specific transcription factors may direct the activating or repressive function of SOX10. Laurette et al. (2015) observed similar enrichments for both MITF and TFAP2A consensus motifs within the set of SOX10-bound sites in 501mel cells, and comparison of SOX10 and MITF ChIP-seq profiles from 501mel cells showed that over half of SOX10-bound sites were co-occupied by MITF. In support of this finding, SOX10 acts synergistically with both MITF and TFAP2A in vitro (Jiao et al., 2004; Wahlbuhl, Reiprich, Vogl, Bosl, & Wegner, 2012) . Together, these data point to a role for SOX10 in the direct transcriptional activation of melanocyte differentiation genes, manifested primarily through enhancer binding and interactions with MITF or other pro-differentiation transcription factors.
Despite its direct regulation of melanocyte differentiation genes, several studies have also implicated SOX10 expression in the survival and proliferation of melanoma. Most melanoma tumors retain SOX10 expression and undergo cell-cycle arrest when SOX10 is lost (Cronin et al., 2013) . In a zebrafish melanoma model, forced overexpression of sox10 promoted tumor formation, whereas knockdown of sox10 reduced it (Kaufman et al., 2016) . Similarly, in mouse models of giant congenital nevi and melanoma, Sox10 haploinsufficiency rescued skin hyperpigmentation and prevented or significantly delayed the formation of malignant tumors (Cronin et al., 2013; Shakhova et al., 2012) .
Furthermore, genes encoding factors that regulate cell cycle and proliferation were downregulated in response to the loss of SOX10 expression, while pro-apoptotic genes were upregulated (Cronin et al., 2013; Shakhova et al., 2012) . These findings support the conclusion that the expression profile of melanoma tumor cells more closely resembles that of multipotent NC cells than differentiated melanocytes (Kaufman et al., 2016) , and suggest a complex role for SOX10 in melanoma progression.
| YY1
Yin Yang 1 (YY1) is so named because it can act as a transcriptional activator, initiator, or repressor depending on the context of its binding (Shi, Lee, & Galvin, 1997) . It was first described as a repressor of the immunoglobulin κ 3′ enhancer during B-cell development and as both a repressor and activator at the adeno-associated virus P5 promoter (Park & Atchison, 1991; Shi, Seto, Chang, & Shenk, 1991) . Since then, YY1 has been studied in many cellular contexts, and evidence for various regulatory mechanisms, including interaction with multiple cofactors, has been extensively reviewed (Gordon, Akopyan, Garban, & Bonavida, 2006; Shi et al., 1997; Thomas & Seto, 1999) . The versatility of YY1 is reflected in its unique protein structure. A member of the GLI-Krüppel family, it contains a highly acidic N-terminal activation domain and four C 2 H 2 zinc fingers at the C-terminal repression/DNAbinding domain, which binds the sequence motif 5′-CGCCATNTT-3′
( Figure 1c ; Bushmeyer, Park, & Atchison, 1995; Shi et al., 1997) . In addition, the recruitment of Polycomb (REPO) domain was found to promote methylation of H3K27 and subsequent gene silencing (Wilkinson, Park, & Atchison, 2006) . A recent study of the YY1 protein structure led to its classification as an intrinsically disordered protein (IDP), characterized by unstructured and flexible regions (Gorecki et al., 2015) . This flexibility may aid YY1 in interacting with many different cofactors to regulate transcription.
Expression of YY1 is widespread, detectable in the mouse as early as the single-cell stage and ubiquitous at stages E7.5-E12.5 (Donohoe et al., 1999) . Accordingly, knockout of Yy1 in mice resulted in embryonic lethality, which occurred after embryo implantation but prior to gastrulation, suggesting that YY1 plays an essential role during the earliest stages of embryonic development. Interestingly, a subset of Yy1 heterozygous mutant mice displayed neural defects and exencephaly, which could reflect a later role in brain development (Donohoe et al., 1999 Sui, 2009 ). This tumorigenic effect has largely been ascribed to the inhibition of p53, but functions of YY1 in cell-cycle regulation, apoptosis, and the recruitment of histone modifiers that promote gene silencing have also been proposed to contribute to its role in cancer (Castellano et al., 2009; Gordon et al., 2006; Sui, 2009 ). Consistent with its broad expression, YY1 appears to be a common regulatory
factor. An analysis of core promoter sequences identified it as the second-highest scoring motif after the TATA box (Xi et al., 2007 
| TFAP2A
The , 1996) . Conditional knockout of Tfap2a in the NC using Wnt1-Cre yielded a range of phenotypes from severe exencephaly to cleft palate, malformation of craniofacial structures and bones of the ear, and defects in the migration of pigment cells to the belly and limbs (Brewer, Feng, Huang, Sullivan, & Williams, 2004) . In humans, TFAP2A mutations can cause branchio-oculo-facial syndrome (BOFS), a rare autosomal dominant disorder that is characterized by craniofacial defects, hearing loss, abnormal development of the eyes and skin, and can include premature hair greying (Milunsky et al., 2008) . Importantly, studies in zebrafish (Knight et al., 2003) and mouse (Brewer et al., 2004; Schorle et al., 1996; Zhang et al., 1996) To test this model, we performed anti-TFAP2A ChIP-seq in human primary melanocytes, which yielded 13,690 TFAP2A peaks, and mouse immortalized melanocytes (melan-a cells), which yielded 16,305 TFAP2A peaks (Seberg et al., 2017) . While 70% of mouse TFAP2A peaks overlapped a signature of active enhancers in melan-a cells, genes with high expression in melanocytes also showed enrichment for promoter-proximal TFAP2A peaks, suggesting that TFAP2A binds both enhancers and promoters. In both mouse and human, approximately 55%-60% of TFAP2A peaks overlapped with ChIPseq peaks for the marker of active regulatory elements H3K27ac, and these "active" TFAP2A peaks were associated with several melanocyte differentiation genes including MC1R, DCT, TYRP1, OCA2, and PMEL.
Many of these genes are candidates for direct targeting by TFAP2A, as microarray profiling showed that their expression is reduced in siTfap2a-transfected mouse melan-a cells and/or tfap2a −/− zebrafish mutants. Furthermore, comparison of TFAP2A ChIP-seq profiles with MITF ChIP-seq from human primary melanocytes (Webster et al., 2014) showed that 77% of the genes that were associated with active TFAP2A peaks were also associated with active MITF peaks, with TFAP2A and MITF peaks overlapping in the majority of cases (Seberg et al., 2017) . Many of these are melanocyte differentiation genes that have been associated with mouse coat color phenotypes. As one example, luciferase reporter assays in M21 melanoma cells indicated that TFAP2A binding actively regulates expression of the 700-base pair promoter element of TRPM1, as previously shown for MITF (Miller et al., 2004) and YY1 . Similarly, TFAP2A and MITF cooperatively regulate the activity of a melanocyte-specific enhancer of IRF4 (Praetorius et al., 2013) . In agreement with these examples, Laurette et al. (2015) found 762 MITF-associated regulatory elements that were co-occupied by MITF, TFAP2A, and YY1. These results suggest that TFAP2A directly regulates the expression of melanocyte differentiation effector genes, likely in conjunction with other TFAP2
paralogs.
Consistent with a role in promoting melanocyte differentiation, TFAP2A appears to act as a tumor suppressor in melanoma. Analysis of melanoma-specific mRNA expression signatures identified TFAP2A
as an important regulator of genes expressed in melanoma versus other tumor types, grouping it with MITF, SOX10, and several other transcription factors . Multiple studies have
shown that TFAP2A expression is frequently decreased in melanoma cell lines and tumor samples relative to benign nevi (Baldi et al., 2001; Karjalainen, Kellokoski, Eskelinen, Alhava, & Kosma, 1998; Tellez et al., 2007; Woenckhaus et al., 2003; Zhuang et al., 2007) . Incidentally, one study found that the expression levels of TFAP2A and TFAP2C were inversely correlated with one another in melanoma cell lines, implying mutual negative regulation of expression (Igoucheva & Alexeev, 2009 ). Transfection of A375SM melanoma cells with TFAP2A reduced both initial tumor formation and metastasis in vivo Jean et al., 1998) . This effect appears to be mediated in part by the re-expression of KIT, which is a direct target of TFAP2A . KIT is required for the normal proliferation, migration, and survival of melanocytes (reviewed in WehrleHaller, 2003) , and kita expression is lost in the melanocytes of tfap2a/e double knockdown zebrafish (Van Otterloo et al., 2010) . In addition, increased methylation was observed at the TFAP2A promoter in melanoma tumor samples compared to primary melanocytes, suggesting that epigenetic silencing of TFAP2A expression contributes to melanoma tumorigenesis (Hallberg et al., 2014) . Overall, these results indicate that TFAP2A collaborates with MITF, as well as SOX10 and YY1, in both melanocytes and melanoma.
| ADDITIONAL MITF COFACTORS AND COLLABORATORS
Transcription factors LEF1, RB1, IRF4, and PAX3 have also been reported to collaborate with MITF in melanocytes, although the frequencies of these interactions have not yet been assessed genomewide.
LEF1, which is activated by canonical Wnt signaling, physically interacts with MITF leading to synergistic activation of DCT expression, and this effect is augmented by the presence of β-catenin . A similar interaction was observed at the promoters of TYR and MITF itself, although in these cases, the presence of β-catenin was required Wang et al., 2015) . Interestingly, TCF1, which is closely related to LEF1, also activated DCT expression in combination with β-catenin, but did not exhibit synergistic activity with MITF . Rb1 cooperates with MITF to activate expression of Tyr and Cdkn1a/p21 Cip1 as determined via luciferase assays in B16 mouse melanoma cells, and ChIP for RB1 in 501mel cells confirmed binding at both of these promoters (Carreira et al., 2005 ). IRF4 appears to cooperatively activate a specific subset of melanocyte differentiation genes with MITF. Genomewide association studies in Europeans identified a single nucleotide polymorphism (SNP) that is strongly associated with fair hair and freckling located in an intron of IRF4 (Han et al., 2008; Sulem et al., 2007) . Combining genotype and whole genome sequence data from the Icelandic population, Praetorius et al. (2013) imputed more than 16,000 SNPs within a 10 megabase pair interval centered on this locus. This analysis revealed that the single SNP rs12203592 in a melanocyte-specific enhancer of IRF4 had a highly significant association with the phenotype.
Knockdown of IRF4 in melanocyte cell lines resulted in decreased expression of TYR, but not DCT, SLC45A2, or SLC24A5. However, in the reciprocal experiment, forced expression of IRF4 alone did not activate TYR, but cooperative activation was observed in the presence of MITF. Finally, in contrast to LEF1, RB1, and IRF4, the paired box transcription factor PAX3 binds to an enhancer of DCT and represses its expression through competitive inhibition of MITF activity (Lang et al., 2005) . Expression of β-catenin was shown to restore DCT expression by displacing PAX3. Notably, Pax3 was also shown to directly activate expression of Tyrp1 in B16 mouse melanoma cells (Galibert, Yavuzer, Dexter, & Goding, 1999) , suggesting that it may also have the ability to collaborate with MITF in some contexts. bind many of the same elements and co-regulate genes involved in adhesion in certain cancers (Liu et al., 2016; Zanconato et al., 2015) .
In one study, Gorkin et al. (2012) used ChIP-seq to profile the binding of chromatin marks H3K4me1 and EP300 in mouse melan-a cells and observed that a signature of two H3K4me1 peaks flanking a peak of EP300 was enriched at enhancers. Based on this signature, they identified 2,489 putative melanocyte enhancers, including proven enhancers near the Sox10 and Tyr genes (Antonellis et al., 2008; Murisier et al., 2007) . These enhancers were then used to train the kmer-SVM classifier, a machine-learning algorithm that detects 6-mers overrepresented in a given set of sequences relative to the whole genome.
As expected, consensus binding sites for MITF were highly enriched.
In addition, 6-mers corresponding to binding sites for SOX10, PAX3, FOS/JUN (AP1), and TEAD1 also showed strong enrichment. A similar set of regulatory factors was observed in a study from Verfaillie et al., (2015) which focused on the distinct transcriptomic signatures of invasive versus proliferating melanoma Verfaillie et al., 2015; Widmer et al., 2012) . Combining RNA-seq expression data with
ChIP-seq profiles for the active chromatin mark H3K27ac and the repressive chromatin mark H3K27me3, they detected regulatory regions associated with each state. Motif analysis of these regions showed that SOX10 and MITF were major regulators of the proliferative state, whereas AP1 and TEAD regulated the invasive state. Notably, AP1 has previously been implicated in melanoma progression (Kappelmann, Bosserhoff, & Kuphal, 2014; Yang, McNulty, & Meyskens, 2004) .
| CONCLUDING REMARKS
The transcription factors reviewed here, and perhaps others, are necessary for normal MITF-responsive gene expression in melanocytes.
ChIP-seq experiments indicate substantial but not complete overlap between the binding profiles of MITF, SOX10, YY1, and TFAP2A
in human (Figure 3a) and between SOX10 and TFAP2A in mouse (Figure 3b ). These patterns suggest that various combinations of MITF collaborators work together at specific regulatory elements, in many cases also colocalizing with H3K27ac and the chromatin modifier BRG1 (Figure 3c ; Laurette et al., 2015) . Further studies will be required to understand the precise interactions and contributions to gene expression associated with this model.
| Biochemical mechanisms remain to be determined
There are several possibilities for the biochemical functions of transcription factors that co-occupy regulatory elements with MITF.
Some MITF collaborators may bind DNA independently of MITF but modify the transactivation signal conferred to RNA polymerase, resulting in a cooperative effect on target gene expression. In vitro analyses reveal that SOX10 (Jiao et al., 2004) , LEF1 , RB1 (Carreira et al., 2005) , and IRF4 (Praetorius et al., 2013) have synergistic effects on gene expression with MITF, and TFAP2A
interacts genetically with MITF in vivo (Seberg et al., 2017) . Other MITF collaborators physically interact with MITF as cofactors. Coimmunoprecipitation and pull-down assays have detected physical interactions between MITF and YY1 , LEF1 , and RB1 (Carreira et al., 2005) . However, none of the transcription factors in this review were pulled down in an affinity purification-mass spectrometry experiment for MITF (Laurette et al., F I G U R E 3 Co-occupancy of MITF, SOX10, YY1, and TFAP2A at regulatory elements in melanocytes. (a) Overlap between peaks of MITF, SOX10, YY1, and TFAP2A binding in human melanocyte or melanoma cell lines. ChIP-seq data from MITF (Webster et al., 2014) , SOX10 (Laurette et al., 2015) , YY1 , TFAP2A (Seberg et al., 2017). (b) Overlap between peaks of SOX10 and TFAP2A binding in mouse melan-a cells. ChIP-seq data from SOX10 (Fufa et al., 2015) , TFAP2A (Seberg et al., 2017) . recruits BRG1 independently at some loci and in cooperation with MITF at others; the choice between these activities is presumably determined by other colocalizing factors (Laurette et al., 2015; Marathe et al., 2017) . Different transcription factor combinations could result in the recruitment of different chromatin modifiers, analogous to the role of ZNF750 during skin differentiation (Boxer, Barajas, Tao, Zhang, & Khavari, 2014) . Some collaborators may also have the ability to displace nucleosomes, as so-called pioneer transcription factors, permitting subsequent binding by MITF. There is evidence that TFAP2A is a pioneer factor for the androgen receptor (Pihlajamaa et al., 2014) .
Resolution of the biochemical functions of MITF collaborators is an important goal toward a detailed understanding of gene regulation in melanocytes and melanoma.
| Contributions to MITF-mediated gene expression are still unclear
The papers we have summarized show that, like other transcription factors, MITF acts in a combinatorial fashion with distinct sets of transcription factors at distinct regulatory elements (Wang et al., 2012) . The specific composition of complexes and timing of transcription factor binding may allow for finely tuned transcriptional control (Biggin, 2011; MacQuarrie, Fong, Morse, & Tapscott, 2011) . We did not observe a clear pattern in gene ontology enrichment among the sets of genes associated with various categories of overlapping ChIPseq signals for MITF, SOX10, YY1, and TFAP2A (Figure 3a) . However, algorithms to assign peaks to genes are imperfect. In addition, ChIPseq profiles alone are inadequate to deduce the gene targets of a transcription factor, as 50% or fewer of the genes associated with peaks of a given transcription factor show functional changes in gene expression (Cusanovich, Pavlovic, Pritchard, & Gilad, 2014) . Peaks that do affect expression of associated genes tend to be at enhancers over promoters, have stronger binding motifs, and be bound by multiple transcription factors (Cusanovich et al., 2014; Paris et al., 2013) . 
+
The observed downregulation of TFAP2A in advanced melanoma (Hallberg et al., 2014) (Figure 4b ; Verfaillie et al., 2015) . This qualitative effect may underlie the observation that SOX10 expression is generally high in melanoma tumors (Cronin et al., 2013) and that sox10 overexpression promoted melanoma tumorigenesis in zebrafish (Kaufman et al., 2016) . Importantly, in both quantitative and qualitative models, MITF collaborators are, like MITF itself, subject to post-translational modifications that reflect aspects of the extracellular milieu. Whether or not the morphogen effector analogy strictly holds in melanoma, it is clear that studies of developmental genetics are highly informative for understanding regulatory circuits in cancer. Systematic genetic studies, in both gain-and loss-of-function modes, followed by iterative mathematical modeling of transcriptional networks (Greenhill et al., 2011) will doubtless provide additional insight into the regulatory control of phenotype switching in melanoma.
